文献速递胸部肿瘤乳腺癌消化系统肿瘤

COVID-19大流行前10个月美国未诊断癌症病例分析

Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic.
PubMed 文献 · JAMA Oncol · 2024-01-01

基于美国50州及哥伦比亚特区癌症登记数据的横截面分析显示,2020年3月至12月全部位癌症观察发病率较预期低13.0%(95%预测区间11.2%-14.9%),估计约134 395例癌症未被诊断;前列腺癌、女性乳腺癌和肺癌遗漏病例数最多;可筛查癌症总发病率降低13.9%,女性乳腺癌在疫情前3个月后出现恢复迹象,而结直肠癌、宫颈癌和肺癌仍处低位。

要点

  • 2020年3月至12月美国全部位癌症观察发病率较预期低13.0%,估计约134 395例癌症未被诊断。
  • 遗漏病例数最多的癌种为前列腺癌(22 950例)、女性乳腺癌(16 870例)和肺癌(16 333例)。
  • 可筛查癌症总发病率降低13.9%;女性乳腺癌在疫情前3个月后出现恢复迹象,结直肠癌、宫颈癌和肺癌仍处低位。

核心结论

  • 这项癌症发病趋势横截面分析发现,COVID-19大流行前10个月美国癌症诊断受到实质性干扰,总体及差异性发现可用于指导美国卫生系统在癌症筛查和检测中应重点弥补的领域。

研究设计与样本

  • 本研究为基于人群的横截面分析,使用2018年1月1日至2020年12月31日美国癌症统计报告的浸润性癌症诊断病例数据,覆盖全部50个美国州和哥伦比亚特区,数据分析于2023年7月6日至28日进行。

主要发现

  • 2020年3月1日至12月31日共报告1 297 874例癌症病例,年龄调整发病率为每10万人326.5例;观察病例中男性657 743例(50.7%),65岁及以上757 106例(58.3%),白人1 066 566例(82.2%)。
  • 全部位癌症观察发病率在COVID-19大流行应对高峰(2020年3月至5月)较预期低28.6%(95%预测区间25.4%-31.7%),2020年6月至12月低6.3%(95%预测区间3.8%-8.8%),大流行前10个月总体低13.0%(95%预测区间11.2%-14.9%)。
  • 上述差异提示该时间段内可能有134 395例(95%预测区间112 544-156 680)癌症未被诊断;前列腺癌遗漏病例数最多(22 950例),其次为女性乳腺癌(16 870例)和肺癌(16 333例)。
  • 可筛查癌症总发病率较预期降低13.9%(95%预测区间12.2%-15.6%);女性乳腺癌发病率在大流行前3个月后显示出恢复至既往趋势的证据,但结直肠癌、宫颈癌和肺癌的发病率水平仍处低位。
  • 2020年3月至5月,COVID-19应对措施更严格的州干扰显著更大,但至2020年12月,除肺癌、肾癌和胰腺癌外,这些差异在所有部位均无统计学显著性。

临床怎么用

  • 原文结论指出,总体及差异性发现可用于指导美国卫生保健系统在癌症筛查和检测中应重点弥补的领域。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The COVID-19 pandemic disrupted the normal course of cancer screening and detection in the US. A nationwide analysis of the extent of this disruption using cancer registry data has not been conducted. OBJECTIVE: To assess the observed and expected cancer rate trends for March through December 2020 using data from all 50 US states and the District of Columbia. DESIGN, SETTINGS, AND PARTICIPANTS: This was a population-based cross-sectional analysis of cancer incidence trends using data on cases of invasive cancer diagnosis reported to the US Cancer Statistics from January 1, 2018, through December 31, 2020. Data analyses were performed from July 6 to 28, 2023. EXPOSURE(S): Age, sex, race, urbanicity, and state-level response to the COVID-19 pandemic at the time of cancer diagnosis. MAIN OUTCOMES AND MEASURES: Used time-series forecasting methods to calculate expected cancer incidence rates for March 1 through December 31, 2020, from prepandemic trends (January 2018-February 2020). Measured relative difference between observed and expected cancer incidence rates and numbers of potentially missed cancer cases. RESULTS: This study included 1 297 874 cancer cases reported in the US from March 1 through December 31, 2020, with an age-adjusted incidence rate of 326.5 cases per 100 000 population. Of the observed cases, 657 743 (50.7%) occurred in male patients, 757 106 (58.3%) in persons 65 years or older, and 1 066 566 (82.2%) in White individuals. Observed rates of all-sites cancer incidence in the US were 28.6% (95% prediction interval [PI], 25.4%-31.7%) lower than expected during the height of the COVID-19 pandemic response (March-May 2020); 6.3% (95% PI, 3.8%-8.8%) lower in June to December 2020; and overall, 13.0% (95% PI, 11.2%-14.9%) lower during the first 10 months of the pandemic. These differences indicate that there were potentially 134 395 (95% PI, 112 544-156 680) undiagnosed cancers during that time frame. Prostate cancer accounted for the largest number of potentially missed cases (22 950), followed by female breast (16 870) and lung (16 333) cancers. Screenable cancers saw a total rate reduction of 13.9% (95% PI, 12.2%-15.6%) compared with the expected rate. The rate of female breast cancer showed evidence of recovery to previous trends after the first 3 months of the pandemic, but levels remained low for colorectal, cervical, and lung cancers. From March to May 2020, states with more restrictive COVID-19 responses had significantly greater disruptions, yet by December 2020, these differences were nonsignificant for all sites except lung, kidney, and pancreatic cancer. CONCLUSIONS AND RELEVANCE: This cross-sectional analysis of cancer incidence trends found a substantial disruption to cancer diagnoses in the US during the first 10 months of the COVID-19 pandemic. The overall and differential findings can be used to inform where the US health care system should be looking to make up ground in cancer screening and detection.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Burus T, Lei F, Huang B, et al. Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic. JAMA Oncol. 2024. PMID: 38386344. doi:10.1001/jamaoncol.2023.6969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。